Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative

BackgroundDrug-drug interaction (DDI) is one of the main contributors to adverse drug reactions and therefore, it is important to study its frequency in the population. We aimed to investigate frequency and concordance on CYP2D6, CYP2C19, and CYP2C9 (CYP2D6/2C19/2C9)-mediated potential DDIs at the L...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Muh. Akbar Bahar, Jens H. J. Bos, Sander D. Borgsteede, Aafje Dotinga, Rolinde A. Alingh, Bob Wilffert, Eelko Hak
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2020-05-01
Ráidu:	Frontiers in Pharmacology
Fáttát:	CYP2D6 CYP2C19 CYP2C9 drug-drug-interaction Lifelines IADB.nl
Liŋkkat:	https://www.frontiersin.org/article/10.3389/fphar.2020.00624/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!